Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) have been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $84.25.
Several equities analysts have recently weighed in on the stock. ValuEngine downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Guggenheim assumed coverage on shares of ANI Pharmaceuticals in a research note on Thursday, September 12th. They issued a “buy” rating and a $76.00 price target on the stock. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 12th. Finally, BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday.
NASDAQ:ANIP opened at $72.69 on Tuesday. The company’s 50-day moving average price is $70.72 and its 200-day moving average price is $71.91. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32. The company has a market cap of $894.26 million, a P/E ratio of 15.77 and a beta of 2.22. ANI Pharmaceuticals has a twelve month low of $36.92 and a twelve month high of $86.96.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.18 by $0.26. The firm had revenue of $54.36 million for the quarter, compared to the consensus estimate of $55.20 million. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period last year, the firm posted $1.13 earnings per share. On average, analysts expect that ANI Pharmaceuticals will post 5.29 earnings per share for the current year.
In other ANI Pharmaceuticals news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $68.21, for a total transaction of $516,963.59. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 98,451 shares of company stock worth $7,006,801 over the last ninety days. 24.70% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ANI Pharmaceuticals by 237.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock valued at $65,000 after purchasing an additional 559 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of ANI Pharmaceuticals by 55,466.7% in the first quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 1,664 shares in the last quarter. BerganKDV Wealth Management LLC acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $141,000. Finally, Convergence Investment Partners LLC acquired a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $164,000. 70.77% of the stock is currently owned by institutional investors.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Story: Why do companies pay special dividends?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.